Comparison tool
Compare peptides
Pick up to three compounds. Useful for deciding whether two peptides in a stack actually do different things, or whether you're paying twice for the same pathway.
Select up to three (1/3)
| Attribute | |
|---|---|
| Category | Sexual health |
| Evidence grade | Strong |
| Also known as | Bremelanotide, Vyleesi |
| Mechanism | Selectively activates MC4R in the hypothalamus, increasing dopaminergic signalling in the medial preoptic area — driving desire itself rather than blood flow, unlike PDE5 inhibitors. |
| Key benefits | Increased sexual desire in both sexes · Works independently of vascular function · Effective as an on-demand dose |
| Side effects | Nausea and vomiting · Flushing · Headache · Transient blood-pressure increase |
| Half-life | About 2.7 hours |
| Administration | Subcutaneous auto-injector, 45 minutes before activity |
| Dosing overview | 1.75 mg as needed, maximum one dose per 24 hours |
| Storage | Room temperature for the approved auto-injector |
| Legal status | FDA-approved (Vyleesi) for premenopausal HSDD; other uses are off-label. |
Dosing figures reflect published literature and commonly reported community protocols. They are informational only.